Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Yervoy Will Be First Choice for BRAF-Negative Malignant Melanoma: Skin Cancer Specialist
September 16, 2015
- Daiichi Sankyo Licenses Thrombus Dissolving Agent from US Firm
September 16, 2015
- MTPC Calls Off Japan PIII Program for Alzheimer’s Treatment
September 16, 2015
- Takeda Joins WIPO Consortium for Neglected Tropical Diseases
September 15, 2015
- Takeda Actos Settlement Expected to Become Effective
September 15, 2015
- Lilly Holds Partnering Event in Japan to Unearth Unique Seeds, R&D Chief Interested in 10-Plus Projects
September 14, 2015
- Takeda, Gencia Join Hands to Develop Novel Mitochondrial Therapeutics
September 14, 2015
- Eisai, Swiss Nonprofit to Jointly Develop Eumycetoma Treatment
September 14, 2015
- Novartis Paid 18.3 Billion Yen to Doctors, Medical Institutions in 2014
September 14, 2015
- Pfizer to Enjoy Monopoly in Asacol Generic Market until December
September 14, 2015
- Fluvoxamine Shows Significant Difference against Placebo for Pediatric Obsessive-Compulsive Disorder in PIII Study: Meiji Seika Pharma
September 14, 2015
- FDA Grants Priority Review Status to Multiple Myeloma Drug Ixazomib: Takeda
September 11, 2015
- Ethical Drug Sales Up 6.5% in July: Crecon Report
September 10, 2015
- MTPC, Biogen Partner Up on Imusera Successor
September 10, 2015
- Sanwa Kagaku, Ube to Codevelop Pruritus Treatment
September 10, 2015
- Clinical Study of JACE for Giant Pigmented Nevus Completed: J-TEC
September 9, 2015
- Sanofi Rolls Out Plaquenil, Lantus XR in Japan
September 8, 2015
- FDA Grants Breakthrough Therapy Designation to Hemophilia A Treatment ACE910: Chugai
September 7, 2015
- MSD Paid 13 Billion Yen to Doctors, Medical Institutions in 2014
September 3, 2015
- Merck Serono Japan Wants to Be Leader in Oncology, Fertility: President
September 3, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…